产品
编 号：F323208
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 332348-12-6
产品详情
生物活性：
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
体内研究：
与静脉给药组相比，Abatacept 减轻了爪水肿，皮下注射多剂量组的爪水肿明显减少 (tobs=2.50)。 Abatacept 在研究剂量范围内表现出线性 PK。NCA 清除率 (CL) 为 20.8 mL/day/kg，容积 (Vss) 为 146 mL/kg，皮下给药的生物利用度 (F) 为 57.7%。 Abatacept (口服；10 mg/kg；每 2 天一次) 降低活化 T 细胞 (CD44highCD62L–) 的比例并抑制纯合子 DO11.10 RAG-2 中 ICOS 和 CD71 的上调–/– BALB/c (H-2d/d) 小鼠。Animal Model:Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:IV or SC
Result:Reduced paw edema, and the SC Multiple-dose group showed significantly greater (tobs = 2.50) paw edema reduction compared with the IV dose group.
Animal Model:Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
Administration:IV or SC
Result:The NCA clearance (CL) is 20.8 mL/day/kg, volume (Vss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
体内研究：
与静脉给药组相比，Abatacept 减轻了爪水肿，皮下注射多剂量组的爪水肿明显减少 (tobs=2.50)。 Abatacept 在研究剂量范围内表现出线性 PK。NCA 清除率 (CL) 为 20.8 mL/day/kg，容积 (Vss) 为 146 mL/kg，皮下给药的生物利用度 (F) 为 57.7%。 Abatacept (口服；10 mg/kg；每 2 天一次) 降低活化 T 细胞 (CD44highCD62L–) 的比例并抑制纯合子 DO11.10 RAG-2 中 ICOS 和 CD71 的上调–/– BALB/c (H-2d/d) 小鼠。Animal Model:Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:IV or SC
Result:Reduced paw edema, and the SC Multiple-dose group showed significantly greater (tobs = 2.50) paw edema reduction compared with the IV dose group.
Animal Model:Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
Administration:IV or SC
Result:The NCA clearance (CL) is 20.8 mL/day/kg, volume (Vss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备